Related Experiment Videos
Antihypertensive effect of nicardipine hydrochloride in essential hypertension
Insights
Nicardipine hydrochloride (YC-93) effectively lowers blood pressure in patients with essential hypertension. This new calcium antagonist demonstrated significant reductions in both systolic and diastolic pressures across two treatment groups.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Essential hypertension is a prevalent cardiovascular condition requiring effective treatment.
- Calcium antagonists represent a key class of antihypertensive medications.
Purpose of the Study:
- To evaluate the antihypertensive efficacy and safety of nicardipine hydrochloride (YC-93).
- To assess YC-93 in patients with mild to moderate essential hypertension.
Main Methods:
- Oral administration of nicardipine hydrochloride (YC-93) at 30-60 mg/day for 8 weeks.
- Two groups were studied: monotherapy (Group I, 31 patients) and combination therapy with diuretics/beta-blockers (Group II, 16 patients).
- Blood pressure and pulse rate were monitored throughout the study.
Main Results:
- Significant reductions in blood pressure were observed in both groups: Group I (173.6/103.5 to 139.7/87.2 mmHg) and Group II (172.9/108.9 to 140.5/89.5 mmHg).
- Pulse rate remained unchanged in Group I and showed a transient increase in Group II.
- Mild and transient side effects, primarily related to vasodilation, were reported in seven patients.
Conclusions:
- Nicardipine hydrochloride (YC-93) is an effective antihypertensive agent for managing essential hypertension.
- The drug is well-tolerated, with most side effects being mild and transient.
- YC-93 shows promise as a therapeutic option for hypertensive patients.
Abstract:
The antihypertensive effect of a new calcium antagonist, nicardipine hydrochloride (YC-93), was studied in 47 mild to moderate essential hypertensives. YC-93 (30-60 mg/day) was administered orally alone for 8 weeks (Group I, 31 patients) or in combination with diuretics, beta blockers, or both (Group II, 16 patients). Blood pressure was reduced from 173.6 +/- 2.2/103.5 +/- 1.7 to 139.7 +/- 2.0/87.2 +/- 1.1 mmHg in Group I and from 172.9 +/- 3.9/108.9 +/- 2.9 to 140.5 +/- 2.3/89.5 +/- 2.5 mm Hg in Group II. Pulse rate was not altered in Group I but increased transiently in Group II. The side effects seen in seven patients were mostly related to the vasodilatation and were generally transient and mild. These results indicate that YC-93 is an effective antihypertensive drug for the treatment of essential hypertension.